Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations

Abstract

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in people with diabetes with no available treatment. AIM To explore the effect of testosterone treatment on liver. Testosterone therapy improves insulin resistance and reduces total body fat, but its impact on the liver remains poorly studied. METHODS This secondary analysis of a 40 wk, randomised, double-blinded, placebocontrolled trial of intramuscular testosterone undecanoate in men with type 2 diabetes and lowered serum testosterone concentrations evaluated the change in hepatic steatosis as measured by liver fat fraction on magnetic resonance imaging (MRI). RESULTS Of 88 patients enrolled in the index study, 39 had..